Loading…
SELLAS Life Sciences Group, Inc. is projected to rise to $12.22 by 2027, a +19% move from its current price of $10.29. SLS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $9.72 | $10.29 | $10.89 | 0.00% |
| Aug 2 | $9.50 | $10.29 | $11.15 | 0.00% |
| Aug 3 | $9.33 | $10.29 | $11.35 | 0.00% |
| Aug 4 | $9.19 | $10.29 | $11.52 | 0.00% |
| Aug 5 | $9.07 | $10.29 | $11.68 | 0.00% |
| Aug 6 | $8.96 | $10.29 | $11.82 | 0.00% |
| Aug 7 | $8.86 | $10.29 | $11.95 | +0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.86 | $10.29 | $11.95 | +0.01% |
| Week 2 | $8.33 | $10.29 | $12.72 | +0.01% |
| Week 3 | $7.94 | $10.29 | $13.34 | +0.02% |
| Week 4 | $7.63 | $10.29 | $13.88 | +0.02% |
| Week 5 | $7.36 | $10.29 | $14.39 | +0.03% |
| Week 6 | $7.13 | $10.29 | $14.85 | +0.03% |
| Week 7 | $6.93 | $10.29 | $15.30 | +0.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
SELLAS Life Sciences Group, Inc. is a Healthcare company described as a late-stage clinical biopharmaceutical company that focuses on the development of novel therapeutics for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 antigen, and SLS009 (tambiciclib), a selective small molecule CDK9 inhibitor.
The company has strategic collaborations with Merck & Co., GenFleet Therapeutics (Shanghai), Inc., and Memorial Sloan Kettering Cancer Center, and is headquartered in New York, New York.
The profile presents SELLAS as a late-stage biopharma player operating in the Healthcare sector, with ticker symbol SLS and a base described in terms of its focus on oncology and related partnerships. It situates the company in the U.S. market and notes its leadership in pursuing cancer therapeutics through collaborations and clinical development.
Overall, the description establishes SELLAS as a United States–based healthcare company focused on cancer therapeutics, with leadership compounds GPS and SLS009 and multiple strategic collaborations, anchored by its New York, NY headquarters.
SELLAS Life Sciences Group, Inc. (SLS) is currently priced around $10.84 per share, and carries a market capitalization of $2.13B. The stock’s current price and market cap place it within the larger biotechnology/healthcare landscape.
In terms of market positioning, the stock is ranked 1885 by market capitalization/size in its universe. This ranking reflects its standing within the broader market, alongside other healthcare companies and biopharma peers.
Looking ahead, the price outlook is bullish over the long term based on the provided forecast. The sequence shows a path of rising averages from 2026 onward, with 2026 average at $10.84 and substantial upside by 2030 ($31.11 avg) and far larger in 2040 ($63.63 avg) and 2050 ($201.23 avg), with a max of $462.83 by 2050. The forecast also indicates a progression of bullish sentiment from 2028 onward and generally strong upside through 2050.
A major floor 66.2% below — a decisive break under it would weaken the trend.
The nearest floor, 24.6% below — buyers have tended to step in here.
The nearest ceiling, 50.1% above — a clean break opens room to run.
A major ceiling 83.3% above — clearing it would confirm fresh momentum.
Key SLS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SLS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.53 | Sell | $10.63 | Sell |
| MA 10 | $11.56 | Sell | $11.22 | Sell |
| MA 20 | $12.43 | Sell | $11.54 | Sell |
| MA 50 | $10.42 | Sell | $10.39 | Sell |
| MA 100 | $7.76 | Buy | $8.52 | Buy |
| MA 200 | $5.36 | Buy | $6.39 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.41 | Neutral |
| Stoch RSI (14) | 6.73 | Buy |
| CCI (20) | -134.15 | Sell |
| Williams %R (14) | -93.94 | Info |
| MACD (12,26,9) | -0.51 | Sell |
| ROC (12) | -23.15 | Sell |
| Bollinger %B (20,2) | 0.09 | Neutral |
| Stochastic %K (14) | 6.06 | Buy |
| TRIX (15) | 0.67 | Buy |
| Awesome (5,34) | -0.90 | Sell |
| Ultimate (7,14,28) | 25.50 | Buy |
| Momentum (10) | -1.46 | Sell |
| Aroon Osc (25) | 12.00 | Buy |
| Hull MA (9) | 9.67 | Buy |
| ADX (14) | 17.69 | Neutral |
| ATR (14) | 0.64 | Info |
The near-term technical picture is bullish, with the current sentiment labeled as BULLISH.
The RSI(14) reading is 50, suggesting a neutral position within a bullish backdrop. The stock trades above the 50-day average and well above the 200-day average, with SMA50 listed at $10.25 and SMA200 at $5.24, indicating near-term positive momentum relative to longer-term trends.
In the next 30 days, the stock’s range spans from a low of $7.30 to a high of $16.08. Immediate support is noted at $7.53, while resistance sits at $15.45, outlining a corridor within which the price may oscillate in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.46 | $10.29 | $15.06 | 0% | Neutral | |
| $8.90 | $12.22 | $18.14 | +19% | Neutral | |
| $11.12 | $16.24 | $25.71 | +58% | Bullish | |
| $13.92 | $21.42 | $35.62 | +108% | Bullish | |
| $18.81 | $30.36 | $52.58 | +195% | Bullish | |
| $19.69 | $33.22 | $59.57 | +223% | Bullish | |
| $16.78 | $29.53 | $54.61 | +187% | Bullish | |
| $20.07 | $36.77 | $69.92 | +257% | Bullish | |
| $19.93 | $37.99 | $74.07 | +269% | Bullish | |
| $20.54 | $40.69 | $81.19 | +295% | Bullish | |
| $29.23 | $64.95 | $142.45 | +531% | Bullish | |
| $92.58 | $205.74 | $473.21 | +19.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.46 | $10.29 | $12.05 | +0.00% |
| August 2026 | $8.21 | $9.84 | $12.20 | -4.39% |
| September 2026 | $8.46 | $10.30 | $13.10 | +4.67% |
| October 2026 | $9.22 | $11.38 | $14.77 | +10.56% |
| November 2026 | $9.20 | $11.48 | $15.13 | +0.88% |
| December 2026 | $8.93 | $11.27 | $15.06 | -1.87% |
Click any year to see its month-by-month SLS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
SELLAS Life Sciences Group, Inc.'s 2026 outlook centres on $10.29, within a $3.46 to $15.06 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, SLS could reach as high as $18.14, with a base case around $12.22 and support toward $8.90 — roughly +19% from $10.29. Price action looks broadly range-bound.
Expect SLS to range from $11.12 to $25.71 through 2028. The $16.24 average target implies a +58% move from current prices. That is up +33% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The SLS price prediction for 2029 points to an average of $21.42 (low $13.92, high $35.62) — a potential gain of +108% on today's $10.29. Momentum favours further upside here.
In 2030, SLS is projected to trade between $18.81 and $52.58, averaging $30.36 — a potential gain of +195% from today's $10.29. That is up +42% on the projected 2029 average. Buyers look set to stay in control over this stretch.
SELLAS Life Sciences Group, Inc.'s 2031 outlook centres on $33.22, within a $19.69 to $59.57 range. That is up +9% on the projected 2030 average. That marks a +223% change versus current levels. Momentum favours further upside here.
By 2032, SLS could reach as high as $54.61, with a base case around $29.53 and support toward $16.78 — roughly +187% from $10.29. Buyers look set to stay in control over this stretch.
Expect SLS to range from $20.07 to $69.92 through 2033. The $36.77 average target implies a +257% move from current prices. That is up +25% on the projected 2032 average. Momentum favours further upside here.
The SLS price prediction for 2034 points to an average of $37.99 (low $19.93, high $74.07) — a potential gain of +269% on today's $10.29. Buyers look set to stay in control over this stretch.
In 2035, SLS is projected to trade between $20.54 and $81.19, averaging $40.69 — a potential gain of +295% from today's $10.29. That is up +7% on the projected 2034 average. Momentum favours further upside here.
SELLAS Life Sciences Group, Inc.'s 2040 outlook centres on $64.95, within a $29.23 to $142.45 range. That is up +60% on the projected 2035 average. That marks a +531% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, SLS could reach as high as $473.21, with a base case around $205.74 and support toward $92.58 — roughly +19.0x from $10.29. Momentum favours further upside here.
Investing $1,000 in SLS today (≈ 97.18173 SLS) could be worth
$19,994.46
+$18,994.46 (+1899%) by 2050 · US Dollar
Based on the average projected SLS price of $205.74 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SLSwould be worth at today's price.
$1,000 invested in SLS on Jul 30, 2025 (≈ 602.409651 SLS) would be worth
$6,198.8
+$5,198.8 (+519.9%) today · 6.20× · US Dollar
Based on a SLS entry price of $1.66 vs. today's $10.29.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.34 | $833.87 | -16.6% |
| 1 month ago | $14.76 | $697.15 | -30.3% |
| 3 months ago | $4.93 | $2,087.22 | +108.7% |
| 6 months ago | $3.77 | $2,729.44 | +172.9% |
| 1 year ago | $1.66 | $6,198.8 | +519.9% |
| All time (5.0y) ago | $9.11 | $1,129.53 | +13.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SLS forecast.
Our base-case forecast reaches $21.00 around 2029.
Implied market cap at $21.00: $4.13B
The multi-year forecast shows substantial upside potential, with the average price rising from $10.84 in 2026 to higher levels in subsequent years. For 2026 the avg is $10.84 with a min of $3.46 and a max of $15.86, and ROI is 0% (Neutral sentiment). By 2027, the avg is $12.77 with a min of $9.29 and a max of $18.97, ROI 17.9% (Neutral).
The trajectory continues higher through 2028 (avg $16.75, min $11.47, max $26.54; ROI 54.6%; Bullish), 2029 (avg $22.18, min $14.41, max $36.91; ROI 104.7%; Bullish), and 2030 (avg $31.11, min $19.27, max $53.90; ROI 187.1%; Bullish).
Beyond 2030, the forecast remains bullish with 2031 avg $33.55 and ROI 209.7%, 2032 avg $29.92 (ROI 176.1%), 2033 avg $37.23 (ROI 243.6%), 2034 avg $37.92 (ROI 250%), and 2035 avg $40.75 (ROI 276.1%). By 2040 the avg is $63.63 (ROI 487.3%), and by 2050 the avg is $201.23 (ROI 1757.2%), with a max of $462.83. These figures illustrate a strong long-run upside potential, though they are estimates and not guarantees.
Tap a question to reveal the answer.
In 2030 the forecast shows an avg price of $31.11, with min $19.27 and max $53.90; ROI 187.1%; sentiment BULLISH.
The forecast through 2027-2050 shows rising average prices and ROI, including 2027 avg $12.77 with ROI 17.9%; 2028 avg $16.75 with ROI 54.6%; 2029 avg $22.18 with ROI 104.7%; 2030 avg $31.11 with ROI 187.1%; 2031 avg $33.55 with ROI 209.7%; 2032 avg $29.92 with ROI 176.1%; 2033 avg $37.23 with ROI 243.6%; 2034 avg $37.92 with ROI 250%; 2035 avg $40.75 with ROI 276.1%; 2040 avg $63.63 with ROI 487.3%; 2050 avg $201.23 with ROI 1757.2%. These are estimates, not guarantees.
Forecast shows 2035 max $81.32, 2040 max $139.58, and 2050 max $462.83, so a $100 level could occur by 2040 or later according to the forecast.
The current price is $10.84.
Sentiment is BULLISH. RSI14 is 50. SMA50 is $10.25 and SMA200 is $5.24. The 30-day range is $7.30 to $16.08. Support is $7.53 and resistance is $15.45.
SELLAS Life Sciences Group, Inc. Community Discussion
0Share your SELLAS Life Sciences Group, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.